Toll Free: 1-888-928-9744

Hepatitis C - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 585 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis C - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatitis C - Pipeline Review, H1 2016', provides an overview of the Hepatitis C pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatitis C

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 Introduction 7 Hepatitis C Overview 8 Therapeutics Development 9 Hepatitis C - Therapeutics under Development by Companies 11 Hepatitis C - Therapeutics under Investigation by Universities/Institutes 19 Hepatitis C - Pipeline Products Glance 21 Hepatitis C - Products under Development by Companies 25 Hepatitis C - Products under Investigation by Universities/Institutes 38 Hepatitis C - Companies Involved in Therapeutics Development 40 Hepatitis C - Therapeutics Assessment 124 Drug Profiles 144 Hepatitis C - Recent Pipeline Updates 422 Hepatitis C - Dormant Projects 518 Hepatitis C - Discontinued Products 543 Hepatitis C - Product Development Milestones 551 Appendix 561
List of Tables
Number of Products under Development for Hepatitis C, H1 2016 32 Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2016 33 Number of Products under Development by Companies, H1 2016 35 Number of Products under Development by Companies, H1 2016 (Contd..1) 36 Number of Products under Development by Companies, H1 2016 (Contd..2) 37 Number of Products under Development by Companies, H1 2016 (Contd..3) 38 Number of Products under Development by Companies, H1 2016 (Contd..4) 39 Number of Products under Development by Companies, H1 2016 (Contd..5) 40 Number of Products under Development by Companies, H1 2016 (Contd..6) 41 Number of Products under Investigation by Universities/Institutes, H1 2016 42 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 43 Comparative Analysis by Late Stage Development, H1 2016 44 Comparative Analysis by Clinical Stage Development, H1 2016 45 Comparative Analysis by Early Stage Development, H1 2016 46 Comparative Analysis by Unknown Stage Development, H1 2016 47 Products under Development by Companies, H1 2016 48 Products under Development by Companies, H1 2016 (Contd..1) 49 Products under Development by Companies, H1 2016 (Contd..2) 50 Products under Development by Companies, H1 2016 (Contd..3) 51 Products under Development by Companies, H1 2016 (Contd..4) 52 Products under Development by Companies, H1 2016 (Contd..5) 53 Products under Development by Companies, H1 2016 (Contd..6) 54 Products under Development by Companies, H1 2016 (Contd..7) 55 Products under Development by Companies, H1 2016 (Contd..8) 56 Products under Development by Companies, H1 2016 (Contd..9) 57 Products under Development by Companies, H1 2016 (Contd..10) 58 Products under Development by Companies, H1 2016 (Contd..11) 59 Products under Development by Companies, H1 2016 (Contd..12) 60 Products under Investigation by Universities/Institutes, H1 2016 61 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 62 Hepatitis C - Pipeline by 3-V Biosciences, Inc., H1 2016 63 Hepatitis C - Pipeline by AbbVie Inc., H1 2016 64 Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H1 2016 65 Hepatitis C - Pipeline by AIMM Therapeutics B.V., H1 2016 66 Hepatitis C - Pipeline by Akshaya Bio Inc., H1 2016 67 Hepatitis C - Pipeline by Altor BioScience Corporation, H1 2016 68 Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H1 2016 69 Hepatitis C - Pipeline by Amarna Therapeutics B.V., H1 2016 70 Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H1 2016 71 Hepatitis C - Pipeline by Arbutus Biopharma Corporation, H1 2016 72 Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 73 Hepatitis C - Pipeline by Benitec Biopharma Limited, H1 2016 74 Hepatitis C - Pipeline by BIOCAD, H1 2016 75 Hepatitis C - Pipeline by Biogenomics Limited, H1 2016 76 Hepatitis C - Pipeline by BioLineRx, Ltd., H1 2016 77 Hepatitis C - Pipeline by Bionor Pharma ASA, H1 2016 78 Hepatitis C - Pipeline by Biota Pharmaceuticals, Inc., H1 2016 79 Hepatitis C - Pipeline by Biotest AG, H1 2016 80 Hepatitis C - Pipeline by Biotron Limited, H1 2016 81 Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1 2016 82 Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H1 2016 83 Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2016 84 Hepatitis C - Pipeline by Celgene Corporation, H1 2016 85 Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 86 Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H1 2016 87 Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 88 Hepatitis C - Pipeline by DEKK-TEC, Inc., H1 2016 89 Hepatitis C - Pipeline by Delpor, Inc., H1 2016 90 Hepatitis C - Pipeline by Digna Biotech, S.L., H1 2016 91 Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H1 2016 92 Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H1 2016 93 Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 94 Hepatitis C - Pipeline by Formune S.L., H1 2016 95 Hepatitis C - Pipeline by Genecode AS, H1 2016 96 Hepatitis C - Pipeline by GeneCure LLC, H1 2016 97 Hepatitis C - Pipeline by Gilead Sciences, Inc., H1 2016 98 Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H1 2016 99 Hepatitis C - Pipeline by GlaxoSmithKline Plc, H1 2016 100 Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 101 Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H1 2016 102 Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H1 2016 103 Hepatitis C - Pipeline by ImmunoBiology Limited, H1 2016 104 Hepatitis C - Pipeline by Immunocore Limited, H1 2016 105 Hepatitis C - Pipeline by Immunomedics, Inc., H1 2016 106 Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 107 Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 108 Hepatitis C - Pipeline by iTherX, Inc., H1 2016 109 Hepatitis C - Pipeline by JN-International Medical Corporation, H1 2016 110 Hepatitis C - Pipeline by Johnson & Johnson, H1 2016 111 Hepatitis C - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 112 Hepatitis C - Pipeline by Kineta, Inc., H1 2016 113 Hepatitis C - Pipeline by LG Life Science LTD., H1 2016 114 Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 115 Hepatitis C - Pipeline by Medivir AB, H1 2016 116 Hepatitis C - Pipeline by Merck & Co., Inc., H1 2016 117 Hepatitis C - Pipeline by Microbio Co., Ltd., H1 2016 118 Hepatitis C - Pipeline by Microbiotix, Inc., H1 2016 119 Hepatitis C - Pipeline by MultiCell Technologies, Inc., H1 2016 120 Hepatitis C - Pipeline by Novartis AG, H1 2016 121 Hepatitis C - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 122 Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 123 Hepatitis C - Pipeline by Pfenex Inc., H1 2016 124 Hepatitis C - Pipeline by Pfizer Inc., H1 2016 125 Hepatitis C - Pipeline by PharmaEssentia Corporation, H1 2016 126 Hepatitis C - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 127 Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H1 2016 128 Hepatitis C - Pipeline by Profectus BioSciences, Inc., H1 2016 129 Hepatitis C - Pipeline by Regulus Therapeutics Inc., H1 2016 130 Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2016 131 Hepatitis C - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 132 Hepatitis C - Pipeline by SEEK Group, H1 2016 133 Hepatitis C - Pipeline by SomaGenics, Inc., H1 2016 134 Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H1 2016 135 Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 136 Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 137 Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 138 Hepatitis C - Pipeline by TGV-Laboratories, H1 2016 139 Hepatitis C - Pipeline by Therapix Biosciences Ltd, H1 2016 140 Hepatitis C - Pipeline by Therapure Biopharma Inc., H1 2016 141 Hepatitis C - Pipeline by Theravectys SA, H1 2016 142 Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2016 143 Hepatitis C - Pipeline by VBI Vaccines Inc., H1 2016 144 Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 145 Hepatitis C - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 146 Assessment by Monotherapy Products, H1 2016 147 Assessment by Combination Products, H1 2016 148 Number of Products by Stage and Target, H1 2016 150 Number of Products by Stage and Mechanism of Action, H1 2016 157 Number of Products by Stage and Route of Administration, H1 2016 164 Number of Products by Stage and Molecule Type, H1 2016 166 Hepatitis C Therapeutics - Recent Pipeline Updates, H1 2016 445 Hepatitis C - Dormant Projects, H1 2016 541 Hepatitis C - Dormant Projects (Contd..1), H1 2016 542 Hepatitis C - Dormant Projects (Contd..2), H1 2016 543 Hepatitis C - Dormant Projects (Contd..3), H1 2016 544 Hepatitis C - Dormant Projects (Contd..4), H1 2016 545 Hepatitis C - Dormant Projects (Contd..5), H1 2016 546 Hepatitis C - Dormant Projects (Contd..6), H1 2016 547 Hepatitis C - Dormant Projects (Contd..7), H1 2016 548 Hepatitis C - Dormant Projects (Contd..8), H1 2016 549 Hepatitis C - Dormant Projects (Contd..9), H1 2016 550 Hepatitis C - Dormant Projects (Contd..10), H1 2016 551 Hepatitis C - Dormant Projects (Contd..11), H1 2016 552 Hepatitis C - Dormant Projects (Contd..12), H1 2016 553 Hepatitis C - Dormant Projects (Contd..13), H1 2016 554 Hepatitis C - Dormant Projects (Contd..14), H1 2016 555 Hepatitis C - Dormant Projects (Contd..15), H1 2016 556 Hepatitis C - Dormant Projects (Contd..16), H1 2016 557 Hepatitis C - Dormant Projects (Contd..17), H1 2016 558 Hepatitis C - Dormant Projects (Contd..18), H1 2016 559 Hepatitis C - Dormant Projects (Contd..19), H1 2016 560 Hepatitis C - Dormant Projects (Contd..20), H1 2016 561 Hepatitis C - Dormant Projects (Contd..21), H1 2016 562 Hepatitis C - Dormant Projects (Contd..22), H1 2016 563 Hepatitis C - Dormant Projects (Contd..23), H1 2016 564 Hepatitis C - Dormant Projects (Contd..24), H1 2016 565 Hepatitis C - Discontinued Products, H1 2016 566 Hepatitis C - Discontinued Products (Contd..1), H1 2016 567 Hepatitis C - Discontinued Products (Contd..2), H1 2016 568 Hepatitis C - Discontinued Products (Contd..3), H1 2016 569 Hepatitis C - Discontinued Products (Contd..4), H1 2016 570 Hepatitis C - Discontinued Products (Contd..5), H1 2016 571 Hepatitis C - Discontinued Products (Contd..6), H1 2016 572 Hepatitis C - Discontinued Products (Contd..7), H1 2016 573


List of Figures
Number of Products under Development for Hepatitis C, H1 2016 32 Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2016 33 Number of Products under Development by Companies, H1 2016 34 Number of Products under Investigation by Universities/Institutes, H1 2016 42 Comparative Analysis by Late Stage Development, H1 2016 44 Comparative Analysis by Clinical Stage Development, H1 2016 45 Comparative Analysis by Early Stage Products, H1 2016 46 Assessment by Monotherapy Products, H1 2016 147 Assessment by Combination Products, H1 2016 148 Number of Products by Top 10 Targets, H1 2016 149 Number of Products by Stage and Top 10 Targets, H1 2016 149 Number of Products by Top 10 Mechanism of Actions, H1 2016 156 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 156 Number of Products by Routes of Administration, H1 2016 163 Number of Products by Stage and Routes of Administration, H1 2016 163 Number of Products by Top 10 Molecule Types, H1 2016 165 Number of Products by Stage and Top 10 Molecule Types, H1 2016 165

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify